ESC Professional Premium Access

High individual variability in LDL-reductions after inclisiran administration in a "real-world setting"

Congress Presentation

About the speaker

Professor Oliver Weingaertner

University hospital Jena, Jena (Germany)
1 follower

4 more presentations in this session

PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease

Speaker: Doctor D. Kannenkeril (Erlangen, DE)


Impact of alirocumab added to high-intensity statin therapy on platelet function in AMI patients: a pre-specified substudy of the randomized, placebo-controlled PACMAN-AMI trial

Speaker: Doctor L. Raber (Bern, CH)


Low-density lipoprotein cholesterol reduction with evolocumab and its use in clinical practice: evidence from swedish national register data

Speaker: Professor M. Svensson (Uppsala, SE)


Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry

Speaker: Professor K. Ray (London, GB)


Access the full session

Lipid-lowering by PCSK9 modulation: what’s new?

Speakers: Professor O. Weingaertner, Doctor D. Kannenkeril, Doctor L. Raber, Professor M. Svensson, Professor K. Ray

About the event


ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb